Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group announced that its Vonoprazan Fumarate Tablets have received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in digestive system therapies, offering a novel treatment option with advantages over conventional proton pump inhibitors, potentially strengthening its market position.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on the development and production of drugs. It is known for its innovative approach in creating therapeutic products, particularly in the area of digestive system treatments.
YTD Price Performance: 20.11%
Average Trading Volume: 143,556,278
Technical Sentiment Signal: Buy
Current Market Cap: HK$66B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue